Genentech financially strong while Amgen struggles
Genentech, the world's second biggest biotech company, has shown a strong performance in the first quarter while its main rival Amgen is trying to regain momentum after a difficult year.
Genentech, the world's second biggest biotech company, has shown a strong performance in the first quarter while its main rival Amgen is trying to regain momentum after a difficult year.
The European Union's (EU) member states must take their responsibilities to implement the biotech policy proposed by the European Commission (EC), said EuropaBio, the EU industry body.
Biotech company MedImmune has finally given in to recent pressure from its shareholders and announced yesterday it is putting itself up for sale.